In 2015, there was a large outbreak of Zika virus (ZIKV) in Brazil. Despite its relatively mild impact on healthy adults, ZIKV infection during pregnancy has been associated with severe birth defects. Currently, there is no ZIKV vaccine available, but several vaccine candidates based on the ZIKV membrane (M) and envelope (Env) structural proteins showed promising results in preclinical and clinical studies. Here, the immunogenicity and protective efficacy of a non-replicating adenoviral vector type 26 (Ad26) that encodes the ZIKV M-Env antigens (Ad26.ZIKV.M-Env) was evaluated in mice and non-human primates (NHP). Ad26.ZIKV.MEnv induced strong and durable cellular and humoral immune responses in preclinical models. Humoral responses were characterized by Env-binding and ZIKV neutralizing antibody responses while cellular responses were characterized by ZIKV reactive CD4 + and CD8 + T cells. Importantly, a single immunization with a very low dose of 4x10 7 vp of Ad26.ZIKV.MEnv protected mice from ZIKV challenge. In NHP, a single immunization with a typical human dose of 1x10 11 vp of Ad26.ZIKV.M-Env also induced Env-binding and ZIKV neutralizing antibodies and Env and M specific cellular immune responses that associated with complete protection against viremia from ZIKV challenge as measured in plasma and other body fluids. Together these data provide the rationale to progress the Ad26.ZIKV.M-Env candidate vaccine to clinical testing.
Introduction
Zika virus (ZIKV) is a mosquito-borne virus that was thought to be restricted to Africa and South-East Asia. Env-specific binding 4 weeks post immunization ( Fig 1A) . Sera were additionally assayed for the presence of ZIKV neutralizing antibody responses by Focus Reduction Neutralization test (FRNT) using the ZIKV-PR strain. A dose-dependent induction (p<0.001, trend analysis) of ZIKV neutralizing titers in serum, 4 weeks after immunization was shown ( Fig 1B) . The ratio between Env-binding and ZIKV neutralizing antibody responses were ( Fig 1C) . The dosedependent induction of Env-specific binding and ZIKV neutralizing antibody titers as well as their correlation were confirmed in Balb/c and SJL mice (parts A-F of S1 Fig) .
The durability of the Env-binding antibody response was evaluated in C57BL/6 mice immunized once with 10 8 , 10 9 or 10 10 vp of Ad26.ZIKV.M-Env. Env-binding antibodies were measured in an in-house developed ELISA that highly correlates (r 2 = 0.979) with the commercially available and widely used ZIKV Env ELISA (Alpha Diagnostics) (part G of S1 Fig) . A dose-dependent induction of Env-specific binding antibodies was observed from 4 weeks after immunization that did not decline over 12 weeks. Notable, the Env-specific antibody response marginally increased in time in the group that received the lowest Ad26.ZIKV.M-Env dose (; p = 0.019, p = 1.000, p = 0.446 for 10 8 , 10 9 or 10 10 vp, respectively, trend analysis of responses over time) (Fig 1D) . 
Ad26.ZIKV.M-Env induces durable cellular immune responses directed against both encoded ZIKV antigens in mice
Cellular responses directed to Env and M-derived peptide pools were measured by IFNγ ELI-SPOT assay in splenocytes of C57BL/6 mice, isolated at 4 or 12 weeks after single immunization with 10 8 , 10 9 or 10 10 vp of Ad26.ZIKV.M-Env. A dose-dependent induction of Env-specific IFNγ response (p<0.001, trend analysis) was detected at 4 weeks post-immunization that was still present at week 12 post immunization (Fig 2A and 2B ). Ad26.ZIKV.M-Env also induced a dosedependent (p<0.001, trend analysis) cellular responses to M-derived peptides 4 weeks after prime immunization that were maintained up to 12 weeks after immunization (Fig 2C and 2D ).
Ad26.ZIKV.M-Env immunization induces ZIKV-reactive CD4 + and CD8

+ T cell in mice
To characterize cytokine producing T-cell populations more closely, intracellular cytokine staining (ICS) followed by FACS analysis was performed using splenocytes of C57BL/6 mice isolated 4 weeks after single immunization with 10 8 , 10 9 or 10 10 vp of Ad26.ZIKV.M-Env. This ICS analysis showed that the Env-directed cellular responses were dominated by IFNγ secreting CD8 + T cells, with at the highest vaccine dose up to 15% of the CD8 + cells being positive for IFNγ (Fig 3B) . However, Ad26.ZIKV.M-Env also induced dose-dependent Env-specific, IFNγ secreting CD4 + T-cell responses after a single immunization, although to a lower extent (up to 0.9% at the highest vaccine dose) (Fig 3A) . to Ad26.ZIKV.M-Env vaccine was included as a sham control. Animals were challenged 4 weeks post immunization with ZIKV strain Brazil-ZKV2015 (ZIKV-BR) via the intravenous route.
Immunization with the various doses of Ad26.ZIKV.M-Env resulted in a dose dependent induction of Env-specific binding antibody titers with seroconversions observed in all animals that received Ad26.ZIKV.M-Env (p 0.001 for all doses compared to Ad26.Empty) (Fig 5A) . All animals that received Ad26.Empty showed detectable ZIKV RNA loads in the serum, with peak titer at day 3 to 4 post-challenge (Fig 5B) . In contrast, mice immunized with 4×10 7 , 2×10 8 or 1×10
9 vp of Ad26.ZIKV.M-Env were all protected against viremia after challenge with ZIKV-BR, as evidenced by undetectable viral RNA loads in the isolated serum samples (p<0.001 for all doses compared to Ad26.Empty) (Fig 5C-5E ).
Ad26.ZIKV.M-Env is immunogenic and provides full protection in rhesus macaques
Immunogenicity and protective efficacy of Ad26.ZIKV.M-Env was further assessed in NHP (rhesus macaques). The animals received a single immunization with a typical human dose of 10 11 vp Ad26.ZIKV.M-Env or formulation buffer as sham control and were challenged subcutaneously with ZIKV-BR 4 weeks post-immunization. Limited safety assessments were performed post-immunization and included the assessment of injection site reactions (using Draize score; part A of S1 Table) , clinical signs (cage side observations), hematology parameters, as well as body weight and body temperature (S2 Table) . The administration of a single full human Ad26.ZIKV.M-Env dose of 1×10 11 vp was well tolerated in all study animals and no vaccine-related adverse effects were noted. Ad26.ZIKV.M-Env induced humoral immune responses in NHP, as shown by the induction of Env-binding antibody titers (Fig 6A) , and ZIKV-PR neutralizing antibody titers ( Fig  6B) , that were significantly higher compared with the response in sham injected animals (p = 0.008 for both comparisons). In addition, there was a significant induction of Env-and M-specific IFNγ secreting PBMCs 4 weeks post immunization with Ad26.ZIKV.M-Env, compared with the response in sham injected animals (p = 0.008) (Fig 6C and 6D) .
All sham-injected NHP showed viral loads in the plasma after ZIKV-BR challenge ( Fig 6E) . In contrast, NHP immunized with Ad26.ZIKV.M-Env were all protected against viremia after challenge with ZIKV-BR, as evidenced by undetectable viral ZIKV RNA loads in plasma samples from these animals (p = 0.008 when compared with sham injected animals) (Fig 6F) . In addition, the ZIKV viral loads in cerebrospinal fluid (CSF), urine, and in saliva after ZIKV-BR challenge were measured at days 3 and 7 post challenge. Whereas ZIKV RNA was detectable in CSF samples of all sham-immunized animals, no virus was detected in CSF samples of Ad26.ZIKV.M-Env vaccinated animals (p = 0.008, compared with sham injected animals) Four weeks after challenge, non-structural protein 1 (NS1)-binding and ZIKV neutralizing antibody responses were assessed as an indicator if sterile protection was achieved. Sham injected, ZIKV-BR challenged animals developed NS1-binding antibody titers as response to replicating ZIKV challenge virus, while NS1 binding antibody titers were low to undetectable in Ad26.ZIKV.M-Env immunized animals that were protected from ZIKV viremia (p<0.001 comparing Ad26.ZIKV.M-Env and sham) (Fig 6G) . As expected, sham-immunized animals developed ZIKV neutralizing titers in serum upon ZIKV challenge. ZIKV neutralizing titers of animals that were immunized with Ad26.ZIKV.M-Env, and protected from ZIKV viremia, remained essentially unchanged upon ZIKV challenge (mean titers of 2.73±0.40 pre-challenge, and 3.24±0.19 post-challenge; p = 0.56) (Fig 6H) .
Discussion
Here we show that Ad26 encoding for ZIKV M and Env is highly immunogenic in several preclinical models. Ad26.ZIKV.M-Env induced strong humoral immune responses in mice and NHP that were characterized by antibodies capable of binding the ZIKV Env protein, and in vitro neutralization of the vaccine-heterologous ZIKV-PR strain. Our vaccine also induced cellular immune responses in both mice and NHP. In Balb/c mice a single low dose immunization with just vp and NHP dosed with 10 11 vp 4 weeks after immunization [8, 9] . The protection in these animal models correlated with Env-specific binding antibody and ZIKV neutralizing antibody responses assessed by serum transfer studies [9, 22] . The immune durability data presented here demonstrate that Env-directed antibody and cellular immune responses induced after a single immunization with Ad26.ZIKV.M-Env are maintained for at least 12 weeks in mice. The second immunization only boosted the CD8 + Tcell responses and not the CD4 + T-cell response or the Env-directed antibody response. This is in alignment withour experience that homologous prime-boost regimens with Ad26-based vaccines rarely increases the antibody response in mice, while in humans the prime response can be boosted by an additional immunization [18] . Our durability results are in accordance with data obtained with Ad26 and RhAd52-based ZIKV vaccine candidates given at high dose encoding for the M-Env antigen, which showed that ZIKV neutralizing antibodies resulted in protection in mice that were challenged 20 weeks after immunization. The durability of protective immune responses induced by RhAd52-M-Env was confirmed in NHP, where ZIKV challenge of RhAd52-M-Env immunized animals at 52 weeks after immunization resulted in complete protection in 100% of the animals. In contrast, a ZIKV DNA vaccine and purified inactivated virus (PIV) provided NHP with complete protection at peak immunity, but did not confer complete protection against challenge at 52 weeks post-immunization [22] .
Longevity of protection has not been assessed in humans yet, however the PIV ZIKV vaccine adjuvanted with alum and two DNA-based vaccines have been evaluated in phase 1 clinical trials. Two immunizations with PIV 4 weeks apart resulted in neutralizing antibody titers in nearly all subjects (92%) at 2-4 weeks after the boost. Human-to-mouse serum transfer studies demonstrated that the induced antibody responses provided partial to complete protection against viremia in ZIKV challenged mice [13] . The response induced by two different DNA-based ZIKV candidate vaccines showed different outcomes depending on the candidate and regimen. The most promising candidate, VRC5283, containing the wild-type prM-Env, yielded in 100% of subjects (14/14) detectable neutralizing antibody responses with the highest geometric mean titers after 3 administrations with a needle-free device with a splitdose (into two arms) [14] . Another DNA-based vaccine encoding for prM-Env showed induction of Env-binding antibodies in 100% of the subjects, while only up to 63% developed ZIKV neutralizing antibody responses and moderate T-cell responses after 3 immunizations. Immune serum transferred to AG129 IFNα knockout mice provided protection against lethal ZIKV challenge in 103 out of 112 recipients (93%) [16] .
It is considered critical for a ZIKV vaccine to induce durable protective immunity. RhAd52-M-Env and Ad26-M-Env both elicit durable protective immunity in mice and RhAd52-M-Env also elicit durable immunity in NHP [22] . Immune responses induced with other Ad26-based vaccine candidates that we already tested in humans are also durable [13] [14] [15] and supportive of moving the Ad26.ZIKV.M-Env ZIKV candidate vaccine into clinical development.
Although neutralizing antibodies have been identified as the primary mechanistic correlate of protection for ZIKV vaccine candidates in NHP and by human-to-mouse serum transfer studies, there is growing evidence that T cells also contribute to protective immunity. It has been shown that mice with impaired CD8 + T-cell compartments are more susceptible to ZIKV challenge [23] and that mice that were infused with DENV-immune CD8 + T cells showed reduced viral burden after ZIKV challenge [24] . These data show that T cells can contribute to protection in the absence of protective antibodies. Here, we show that robust cellular responses were induced in mice and NHP. In mice, the cellular responses were predominantly characterized by CD8 + T cells secreting IFNγ or TNFα, although relatively high levels of CD4 + responding T cells were also induced upon immunization and that these cellular responses were maintained for at least 12 weeks. During Phase 1 evaluation of DNA-based ZIKV vaccine candidates limited but significant CD4 + and CD8 + T-cell responses were induced [14, 16] . In NHP, two immunizations with alum adjuvanted PIV has been shown to induce cellular responses in the same range as a single immunization with RhAd52-M-Env [8] . Although human ZIKV disease is relatively mild in healthy adults, ZIKV can cause severe birth defects in fetuses of ZIKV positive pregnant women that are associated with dysfunction of ZIKV infected neuroprogenitor cells [25] . There are strong indications that ZIKV efficiently replicates in fetal tissue, forming a viral reservoir that could be the reason for the observed prolonged viremia (>14 days) during pregnancy compared with non-pregnant individuals (7-10 days) [26, 27] . Several preclinical models have been used to study vaccine efficacy during pregnancy. It has been shown that transferred ZIKV specific monoclonal antibodies or immune responses induced by mRNA-based or live attenuated ZIKV candidate vaccines were able to prevent fetal demise in mice [28] [29] [30] . Studying infection in pregnant mice might yield valuable information regarding the ability of the vaccine to prevent birth defects. However, NHP more closely resemble human gestation, including placentation, brain structure and neurodevelopment and are considered more appropriate for studying infection in pregnancy [31] . Recently several studies investigated the impact of ZIKV infection during pregnancy in NHP and showed that neurological pathology occurred in brains of fetuses of infected pregnant NHP, particularly when ZIKV inoculation occurred early in pregnancy [7, [32] [33] [34] [35] . These models could be suitable to test intervention strategies including vaccination to prevent fetal infection. Since ZIKV seems to replicate more efficiently during pregnancy, it is likely necessary to achieve near sterile protection by vaccination to prevent congenital Zika syndrome. It remains to be elucidated whether the observed protection induced by Ad26.ZIKV.M-Env in NHPs directly translates into prevention of congenital Zika syndrome or that Ad26.ZIKV.M-Env might indirectly contribute to prevention of congenital Zika syndrome by heard immunity.
Protective efficacy of Ad26.ZIKV.M-Env against ZIKV viremia in NHP resulted in near undetectable NS1-binding antibody titers four weeks after ZIKV challenge in Ad26.ZIKV. M-Env immunized animals. The NS1 protein is not associated with ZIKV viral particles nor is it one of the components of Ad26.ZIKV.M-Env, and is thus only presented to the immune system by infected cells [36] . Therefore, the NS1 ELISA results suggest near sterile protection was achieved in NHP that received a single Ad26.ZIKV.M-Env immunization. In contrast, sham injected animals displayed viral load after ZIKV challenge and developed robust NS1 titers.
The robust induction of NS1-binding antibodies after ZIKV exposure in non-protected NHPs, and the near-absence of NS1-binding antibody titers in ZIKV exposed protected animals suggests that NS1-binding antibody responses could be used as surrogate clinical readout for ZIKV infection in efficacy studies. This would have a significant benefit over molecular-based virology readouts with a narrow detection window for ZIKV RNA in ZIKV infected humans [37, 38] . It has already been shown that serodiagnostics of ZIKV infections based on NS1-reactive antibodies is highly accurate and avoids false positive detection of ZIKV as a result of crossreactive antibodies induced by other Flaviviridae such as Dengue virus (DENV) [39, 40] . 
Materials and methods
Ethical statement
All mouse studies were compliant with the Dutch Law and Guidelines on the 
M-Env of the immunogenicity experiment and one Balb/c mouse of in the group that received
Ad26 encoding ZIVK M-Env is immunogenic and protects mice and NHP against ZIKV viremia 1x10 9 vp of Ad26.ZIKV.M-Env of the challenge experiment died during the blood collection due to technical failures. At the end of the studies, mice of the immunogenicity studies were euthanized by cervical dislocation under isoflurane anesthesia and mice included in the challenge study were euthanized by CO 2 exposure after isoflurane anesthesia. A total of 51 C57BL/ 6, 18 SJL and 18 Balb/c mice were used in the immunogenicity experiments and 34 Balb/c mice were used in the challenge experiment. The NHP research protocols was approved by the BIOQUAL's IACUC (protocol number 17-017) and were in compliance with the Animal Welfare Act, Public Health Service Policy on humane care and use of laboratory animals, and other federal statutes and regulations relating to animals and experiments involving animals. The studies were conducted in one of BIOQ-UAL's AAALAC (International Association for the Assessment and Accreditation of Laboratory Animal Care) accredited facilities. Ten outbred, Indian-origin, macaca mulatta (rhesus macaque) between the ages of 3-8 years were purchased from PrimGen, Inc. (Hines, IL). NHPs were housed singly during the study period to avoid transmission of virus between animals in a 2-or 4-pack cage system according to AAALAC and United States Department of Agriculture (USDA) standards. Each cage had a floor area of 4.3-6.0 sq. ft and a height of at least 30 inches. During the course of the study, animals were provided structural (perch), inanimate (manipulable toys), and food enrichment. Food enrichment was provided at 5-7 days per week and consisted of portions of fruits and vegetables. Additional enrichment (foraging tasks, etc) were provided at least once a week. Cage side animal health observations were performed twice daily and evaluated according to a standardized scoring rubric. No clinical signs or abnormalities were observed during the in vivo phase of the study. For all biological procedures, the animals were anesthetized intramuscularly with 10 mg/kg ketamine. Euthanasia was performed in accordance with the recommended method of the Panel on Euthanasia of the American Veterinary Medical Association. Animals were sedated prior to administration of an overdose of pentobarbital sodium via the intravenous route.
Vaccine, immunization and challenge
Ad26.ZIKV.M-Env is a monovalent recombinant Ad26-based ZIKV vaccine candidate that encodes for ZIKV membrane (M) lacking the peptide precursor (pr), and envelope (Env) antigens (amino acids 216-794 of the polyprotein) derived from the ZIKV strain BeH815744 [41] . The vaccine was produced on the human PER.C61 cell line and purified and characterized as described previously [19] . Ad26 particle concentrations were determined by optical density at 260nm and viral infectivity by TCID50 assay. All vaccine preparations were tested for bioburden and endotoxin levels (MicroSafe, Millipore, Leiden, The Netherlands) and have passed pre-set release criteria for animal experiments.
Mice were intramuscularly immunized in the quadriceps of the hind legs with 100 μl (50 μl per leg) containing various doses of Ad26.ZIKV.M-Env or Ad26.Empty under isoflurane anesthesia. ZIKV challenges were performed 4 weeks after immunization with 10 5 vp (corresponding to 10 2 PFU) ZIKV-BR (Brazil ZKV2015; Genbank KU497555.1) in 100 μL via the retro orbital intravenous route under isoflurane anesthesia. NHP received a single intramuscular injection with 0.5 ml containing 10 11 vp Ad26.ZIKV.
M-Env or formulation buffer and were challenged 4 weeks later with 10 6 vp (corresponding to 10 3 PFU) of ZIKV-BR via the subcutaneous route.
Env ELISA
Mouse or NHP IgG antibodies to ZIKV Env were measured by ELISA, using a commercially available kit (Alpha Diagnostics mouse, RV-403120-1; NHP, RV-403110-1). Serially diluted serum samples and controls were applied to 96-well Env pre-coated plates. ZIKV Env-specific antibodies were detected by HRP-labeled anti-mouse or anti-monkey IgG (30 min at RT) and 3,3',5,5'-Tetramethylbenzidine (TMB) substrate. The reaction was stopped, followed by optical density measurement at 450 nm. The titer was determined as the log10 value of first dilution above 2x background (mouse) or 5x the background (NHP) that was defined as the OD value of naïve serum. The lower limit of detection defined as one dilution step below the start dilution of the samples (0.92 on log10 scale). Alternatively, Env-binding IgG responses in mice were determined by an in house developed ELISA that highly correlates to the commercially available Alpha Diagnostics mouse ELISA (S1 Fig). In brief, 96-well plates were coated overnight with ZIKV recombinant Env protein (Meridian Life Sciences, R01635). On the next day plates were washed and blocked for 1 h with PBS containing 2% bovine serum albumin (Sigma, A7030-10G). Serially diluted serum samples, controls and serial dilution of mAb ZV-67 (Absolute Antibody, AB00812-2.) as standard were added. Plates were incubated for 1 h at RT. After washing, ZIKV Env-specific mouse antibodies were detected using an HRP-labeled anti-mouse IgG (KPL, 474-182) (1 h at RT) followed by a washing step and luminescence readout with LumiGlow substrate (Sera Care, 5430-0041) for 30 minutes. The log10 relative potency of a sample was calculated as the log10 ratio of the IC50 of the sample over the standard on the same plate. The IC50 values of the samples and standard on a plate were derived from a 4-parameter logistic curve fit per sample or standard with a common upper and lower asymptote and a common slope across samples and standard. The reported Env-specific antibody titers were defined as the log10 of the relative potency multiplied by 1000.
Viral loads by RT-PCR
ZIKV viral loads were determined by RT-PCR as previously described [8] . Briefly, RNA was extracted from serum/plasma or other body fluids with a QIAcube HT purification kit (Qiagen, Hilden, Germany). The viral RNA was converted to cDNA using Superscript III reverse transcriptase with reverse primers targeting ZIKV Capsid. cDNA was subjected to RT-PCR using a TaqMan assay directed to CAP. In each run, a standard series of CAP mRNA was included to quantify the RNA in the samples. Final viral loads were calculated as virus particles per mL serum by multiplying the titer as determined by the RT-PCR with the total of the dilution factors of the individual steps. The limit of detection was 100 copies per mL or per 10 6 cells.
ZIKV neutralization assay (FRNT)
Focus reduction neutralization tests (FRNT) were conducted at Southern Research (Frederick, MD, USA). Vero cells were seeded at a concentration of 2x10 4 cells/well in 96-well plates 24 h prior to the assay initiation. Heat-inactivated serum samples were serially diluted prior to being mixed and incubated with input virus ZIKV-PR (strain PRVABC59) for 1 h at 37˚C. Cell-seeded 96-well plates were infected with 100 μl of the virus/serum mixtures for 1 h before the addition of agarose containing overlay media. Each serum dilution was tested in triplicate wells. Approximately 24 h after infection, ZIKV foci were detected using an anti-flavivirus detection antibody (Millipore, MAB10216), a horseradish peroxidase (HRP)-conjugated secondary antibody (Seracare, 5220-0341), and TrueBlue™ peroxidase substrate (KPL, 71-00-65). ZIKV foci were visualized and counted using an ImmunoSpot analyzer. Neutralizing antibody titers are reported as the inverse of the serum dilution estimated to reduce the number of input virus by 50% (FRNT50). 
IFNγ ELISPOT
Intracellular cytokine staining (ICS)
Freshly isolated mouse splenocytes were stimulated with Env or M-derived peptide pools (JPT, PM-ZIKV-E and PM-ZIKV-M; 4μg/ml per peptide) or medium as negative control and were co-stimulated with hamster anti-mouse CD28 (BD bioscience, 553294) and rat anti-mouse CD49d (BD bioscience, 553153) for 1 h before Golgiplug (containing Brefeldin A; BD Biosciences, 51-2301KZ) was added. After~12 hs incubation at 37˚C, 10% CO 2 , LIVE/DEAD1 Fixable Violet Dead Cell staining (Invitrogen, L34955) was added for dead cell exclusion. Nonspecific binding of surface antibodies was blocked by purified rat anti-mouse CD16/CD32 (BD Biosciences, 553142) and followed by cell surface staining with fluorescently labeled antibodies: FITC hamster anti-mouse CD3e (553062), PE/CP Cy5. 
Statistical analysis
Most mouse immunogenicity experiments presented in this manuscript were exploratory of nature and only post-hoc trend analysis of the dose dependency of the responses using the nonparametric Jonckheere-Terpstra test with the Ad26.empty group set as lowest dose was performed. For the comparison between prime and prime-boost regimens of Ad26.ZIKV.001 in C57BL/6 mice, Env-binding titers in serum and the different cellular readouts in the prime only regimen were compared to the responses in the prime-boost regimen in an across dose comparisons at the different sampling time points by ANOVA. In addition, to test whether antibody levels were maintained, trend analysis of repeated measurements in time was performed.
For the mouse efficacy studies, breakthrough rates of the Ad26.ZIKV.M-Env candidate with doses 4x10 7 , 2x10 8 and 1x10 9 were compared to the Ad26.Empty negative control group using a 2-sided Fisher's exact test with two-fold Bonferroni adjustment, since a second vaccine candidate was included in the experiment that is out of scope of this manuscript, and using a stepwise approach starting with the highest dose per candidate. This stepwise approach was performed under the assumption that for each candidate the higher doses give lower breakthrough. For the area under the curve (AUC) viral load and Env-binding antibody responses the comparisons with the negative control group was done in the same way as for the breakthrough rate except that the Wilcoxon rank-sum test was used instead of Fisher's exact test. For the NHP challenge data the outcome of viral titer in plasma, CSF, urine and saliva measured by RT-qPCR during the challenge phase was summarized as AUC and compared between sham injected and Ad26.ZIKV.M-Env immunized NHPs with the Wilcoxon ranksum test. Env-and NS1-binding and ZIKV neutralizing antibody responses induced by sham injection or Ad26.ZIKV.M-Env immunization were also compared using the Wilcoxon ranksum test.
All statistical analyses were performed using SAS version 9.4 (SAS Institute Inc., USA) or R version 3.3.3. Statistical significance level was set at α = 0.05. Table. A: Draize scores were determined before vaccination (day 0 + 0h), 6h after vaccine administration (day 0 + 6h) and daily for 3 consecutive days post immunization according to the scoring system (S1B Table) . In case any reaction was noted at day 3, scoring continued until reaction completely resolved. '-' indicates that no scoring was performed. B: Overview methodology draize scoring.
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